The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT) (CONCERT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03881852
Recruitment Status : Completed
First Posted : March 20, 2019
Results First Posted : August 24, 2023
Last Update Posted : August 24, 2023
Sponsor:
Information provided by (Responsible Party):
Axsome Therapeutics, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
CONCERT (Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment) is a Phase 2, double-blind, randomized, placebo-controlled, crossover, multicenter trial of AXS-12 in patients with narcolepsy. Subjects meeting the entry criteria will be randomized in a 1:1 ratio either to placebo for three weeks followed by AXS-12 (up to 10 mg daily) for three weeks, or to AXS-12 (up to 10 mg daily) for three weeks followed by placebo for three weeks. Efficacy assessments will include the frequency of cataplexy attacks, and measures of other symptoms of narcolepsy.

Condition or disease Intervention/treatment Phase
Narcolepsy Cataplexy Narcolepsy Excessive Sleepiness Drug: AXS-12 (Reboxetine) Drug: Placebo Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-center, Randomized, Double-blind, Placebo-controlled, 3-Week Crossover Study to Assess the Efficacy and Safety of AXS-12 in Subjects With Cataplexy and Excessive Daytime Sleepiness in Narcolepsy
Actual Study Start Date : January 30, 2019
Actual Primary Completion Date : November 27, 2019
Actual Study Completion Date : November 27, 2019

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: AXS-12 (reboxetine) Drug: AXS-12 (Reboxetine)
Dosed orally, twice daily for up to 3 weeks
Placebo Comparator: Placebo Drug: Placebo
Dosed orally, twice daily for up to 3 weeks


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change From Baseline in the Weekly Average Total Number of Cataplexy Attacks [ Time Frame: 2 weeks ]
    Presented as LSmeans. A positive change is indicative of improvement.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Male or female subjects between 18 and 70 years of age, inclusive
  • Primary diagnosis of narcolepsy with cataplexy
  • Willing and able to comply with the study requirements

Exclusion Criteria:

  • Other clinically significant conditions potentially causing EDS
  • Clinically significant psychiatric disorders
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03881852


Locations
Layout table for location information
United States, Alabama
CONCERT Study Site
Birmingham, Alabama, United States, 35213
United States, California
CONCERT Study Site
Alameda, California, United States, 94501
CONCERT Study Site
Santa Ana, California, United States, 92705
United States, Colorado
CONCERT Study Site
Boulder, Colorado, United States, 80301
United States, Florida
CONCERT Study Site
Miami, Florida, United States, 33126
CONCERT Study Site
Saint Petersburg, Florida, United States, 33707
United States, Georgia
CONCERT Study Site
Gainesville, Georgia, United States, 30501
United States, Indiana
CONCERT Study Site
Fort Wayne, Indiana, United States, 46804
United States, Maryland
CONCERT Study Site
Chevy Chase, Maryland, United States, 20815
United States, New York
CONCERT Study Site
Bronx, New York, United States, 10467
United States, Ohio
CONCERT Study Site
Cincinnati, Ohio, United States, 45219
United States, South Carolina
CONCERT Study Site
Columbia, South Carolina, United States, 29201
United States, Texas
CONCERT Study Site
Austin, Texas, United States, 78731
CONCERT Study Site
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Axsome Therapeutics, Inc.
  Study Documents (Full-Text)

Documents provided by Axsome Therapeutics, Inc.:
Study Protocol and Statistical Analysis Plan: Study Protocol and SAP  [PDF] April 25, 2019
Statistical Analysis Plan: SAP only  [PDF] November 12, 2019

More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Axsome Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT03881852    
Other Study ID Numbers: AXS-12-201
First Posted: March 20, 2019    Key Record Dates
Results First Posted: August 24, 2023
Last Update Posted: August 24, 2023
Last Verified: August 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Axsome Therapeutics, Inc.:
CONCERT
AXS-12
EDS
Cataplexy
 Narcolepsy
Axsome
Reboxetine
Additional relevant MeSH terms:
Layout table for MeSH terms
Narcolepsy
Cataplexy
Sleepiness
Disorders of Excessive Somnolence
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders
Reboxetine
 Antidepressive Agents
Psychotropic Drugs
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs